Ultimovacs

Ultimovacs

A pharmaceutical company developing novel immunotherapies against cancer.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor investor investor

€0.0

round
investor

€0.0

round
N/A

€0.0

round
investor

€0.0

round
N/A

NOK270m

Post IPO Equity
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
EUR2018201920202021202220232024
Revenues0000000000000000000000000000
EBITDA0000000000000000000000000000
Profit0000000000000000000000000000
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000

Source: Company filings or news article

More about Ultimovacs
Made with AI
Edit

Ultimovacs is a pharmaceutical company focused on developing novel immunotherapies to treat cancer. The company operates in the biotechnology and pharmaceutical sectors, targeting a global market of cancer patients and healthcare providers. Ultimovacs' core product is UV1, a universal cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells. The company primarily serves patients with advanced stages of cancer, including metastatic melanoma and ovarian cancer. Ultimovacs' business model revolves around extensive research and development, clinical trials, and eventual commercialization of its immunotherapy products. Revenue is generated through partnerships, grants, and future sales of approved therapies. The company has achieved significant milestones, including FDA Orphan Drug Designation for UV1 and the initiation of multiple Phase II clinical trials.

Keywords: immunotherapy, cancer vaccine, UV1, metastatic melanoma, ovarian cancer, clinical trials, FDA approval, biotechnology, pharmaceutical, immune system.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Ultimovacs

Edit
Zelluna Immunotherapy
ACQUISITION by Ultimovacs Dec 2024